Ori Kalid is an accomplished professional in the biotechnology and pharmaceutical fields, currently serving as Vice President of Research and Development at Protalix Biotherapeutics since June 2024. Prior experience includes leadership roles such as Head of Life Science at Hotaru Innovation Partners and Chief Executive Officer at Silverskate Bio Ltd. Ori Kalid co-founded Pi Therapeutics, where the role of CEO has been held since March 2015. A strong background in drug discovery and translational research is evident from previous positions such as Director of Translational Research at Karyopharm Therapeutics Inc. and Director of Computational Drug Discovery at Epix Pharmaceuticals. Educational qualifications include a Ph.D. in Computational Biology and multiple degrees in Biotechnology, Mathematics, and Computer Science from Tel Aviv University.